Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.
Latest from Alaric DeArment
Sales for the drug grew significantly, with an exec telling the fourth-quarter earnings call that patients with achondroplasia tend to stick with the drugs they are using.
The agency sent the neuroscience-focused company a refuse-to-file letter for the drug as a treatment for IH, a disease with only one drug approved and few in development.
The FDA approved Vimkunya on 14 February as the first vaccine for preventing chikungunya in adolescents as well as adults.
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
The biotech disclosed that its norovirus vaccine program was under US FDA hold due to a case of Guillain-Barré syndrome, but said this would not affect timelines.
Biotech execs and lobbyists try to explain the Trump Administration's policy strategy and how to thrive in it.